Naltrexone maintenance for heroin dependence: uptake, attrition and retention

References

• Kleber HD. Naltrexone. J Subst Abuse Treat 1985; 2: 117–22.
   Google Scholar
• Willette RE, Barnett G. Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations. Rockville, MD: US Department of Health and Human Services, Public Health Services, National Institutes of Health, 1981.
   Google Scholar
• Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O’Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64: 1044–53.
   Google Scholar
• O’Malley SS, Croop RS, Wroblewski JM, Labriola DF, Volpicelli JR. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann 1995; 25: 681–8.
   Google Scholar
• Gonzalez JP, Brogden RN. Naltrexone—a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid depen- dence. Drugs 1988; 35: 192–213.
   Google Scholar
• O’Brien C P. Summary. J Clin Psychiatry 1984; 45: 57–8.
   Google Scholar
• Kleber HD. Ultrarapid opiate detoxification. Addiction 1998; 93: 1629–33.
   Google Scholar
• O’Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomised trial. Ann Intern Med 1997; 127: 526–30.
   Google Scholar
• Seone A, Carrasco G, Cabre´ L et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. Br J Psychiatry 1997; 171: 340–5.
   Google Scholar
• Gerra G, Marcato A, Caccavari R et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12: 35–41.
   Google Scholar
• Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 1981; 7: 235–46.
   Google Scholar
• National Research Council Committee on Clinical Evalua- tion of Narcotic Antagonists. Clinical evaluation of naltrex- one treatment of opiate-dependent individuals. Arch Gen Psychiatry 1978; 35: 335–40.
   Google Scholar
• Sideroff SI, Charuvastra VC, Jarvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1978; 5: 415–23.
   Google Scholar
• Fram DH, Marmo J, Holden R. Naltrexone treatment: the problem of patient acceptance. J Subst Abuse Treat 1989; 6: 119–22.
   Google Scholar
• Greenstein RA, Arndt IC, McLellan AT, O’Brien CP, Evans B. Naltrexone: a clinical perspective. J Clin Psychia- try 1984; 45: 25–28.
   Google Scholar
• Hollister LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 1977; 2: 203–9.
   Google Scholar
• Schifano E, Marra R. Naltrexone for heroin addiction: Encouraging results from Italy. Int J Clin Pharmacol Ther Toxicol 1990; 28: 144–6.
   Google Scholar
• Tennant FS, Rawson RA, Cohen MA, Mann A. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984; 45: 42–5.
   Google Scholar
• Arndt I, McLellan AT, O’Brien CP. Abstinence treatments for opiate addicts: therapeutic community or naltrexone? 45th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc.: drug abuse treatment, 1983, Lexington, KY. National Institute on Drug Abuse Research Monograph Series, 1984; 49: 275–81.
   Google Scholar
• Shufman EN, Porat S, Witztum E, Gandacu D, Bar- Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994; 35: 935–45.
   Google Scholar
• Tucker TK, Ritter A. Naltrexone in the treatment of heroin dependence: a literature review. Drug Alcohol Rev 2000; 19: 73–82.
   Google Scholar
• Foy A, Sadler C, Taylor A. An open trial of naltrexone for opiate dependence. Drug Alcohol Rev 1998; 17: 167–74.
   Google Scholar
• Hulse GK, Basso MR. Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug Alcohol Rev 1999; 18: 263–9.
   Google Scholar
• Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev 2000; 19: 41–8.
   Google Scholar
• O’Brien CP, Greenstein R, Woody GE. Update on naltrexone treatment. International challenge of drug abuse, Rockville, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1978: 315–20.
   Google Scholar
• Hollister LE, Johnson K, Boukhabza D, Gillespie HK. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 1981; 8: 37–41.
   Google Scholar
• Lewis DC, Mayer J, Hersch RG, Black R. Narcotic antagonist treatment: clinical experience with naltrexone. Int J Addict 1978; 13: 961–73.
   Google Scholar
• Schecter A. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone. Am J Drug Alcohol Abuse 1980; 7: 1–18.
   Google Scholar
• Singleton EG, Sherman MF, Bigelow GE. The index of choice: indications of methadone patients’ selection of naltrexone treatment. Am J Drug Alcohol Abuse 1984; 10: 209–21.
   Google Scholar
• Rawson RA, McCann MJ, Shoptaw SJ et al. Naltrexone for opioid dependence: evaluation of a manualized psychosocial protocol to enhance treatment response. Drug Alcohol Rev 2001; 20: 67–78.
   Google Scholar
• Capone T, Brahen L, Condren R, Kordel N, Melchionda R, Peterson M. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol 1986; 42: 825–33.
   Google Scholar
• Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984; 45: 46–8.
   Google Scholar
• Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxifica- tion: an open label naturalistic study. Drug Alcohol Depend 1997; 47: 77–86.
   Google Scholar
• Resnick RB, Kestenbaum RS, Washton A, Poole D. Naltrexone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clin Pharmacol Ther 1977; 21: 409–13.
   Google Scholar
• Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psy- chiatry 1984; 45: 39–41.
   Google Scholar
• O’Brien CP, Greenstein RA, Mintz J, Woody GE. Clinical experience with naltrexone. Am J Drug Alcohol Abuse 1975; 2: 365–77.
   Google Scholar
• Iraurgi I, Jime´nez-Lerma JM, Landabaso MA, Arrazola X, Gutie´rrez-Fraile M. Gipsies and drug addictions. Eur Addict Res 2000; 6: 34–41.
   Google Scholar
• Garc´ıa-Alonso F, Gutierrez M, San L et al. and the Spanish Study Group in Drug Addiction. A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989; 23: 117–21.
   Google Scholar
• Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone compliance with contingency management. Drug Alcohol Depend 1999; 54: 127–35.
   Google Scholar
• Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care profes- sionals. J Subst Abuse Treat 1997; 14: 19–22.
   Google Scholar
• Landabaso MA, Iraurgi I, Jimenez-Lerma JM et al. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 1998; 93: 739–44.
   Google Scholar
• Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? Research Monograph Series Rockville, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1995.
   Google Scholar
• Cornish JW, Metzger D, Woody GE et al. Naltrexone pharmacotherapy for opioid dependent federal proba- tioners. J Subst Abuse Treat 1997; 14: 529–34.
   PubMed Web of Science ®Google Scholar
• Grey CC, Osborn E, Reznikoff M. Psychosocial factors in outcome in two opiate addiction treatments. J Clin Psychol 1986; 42: 185–9.
   Google Scholar
• Ling W. Naltrexone: the clinical investigator’s dilemma. International challenge of drug abuse, 26. Rockville, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1978: 308–14.
   Google Scholar
• American Psychological Association. Diagnostic and statis- tical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
   Google Scholar
• Peachey JE, Lei H. Assessment of opioid dependence with naloxone. Br J Addict 1988; 83: 193–201.
   Google Scholar
• Rothman RB, Gorelick DA, Heishman SJ et al. An open- label study of a functional opioid ? antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000; 18: 277–81.
   Google Scholar
• Erikson EH. Identity: youth and crisis. New York: Norton, 1968.
   Google Scholar
• Mahoney MJ. Human change processes: the scientific foundations of psychotherapy. New York: Guilford, 1991:177.
   Google Scholar